Format

Send to

Choose Destination
J Control Release. 2019 Jul 18;309:1-10. doi: 10.1016/j.jconrel.2019.07.024. [Epub ahead of print]

Ultrasound/microbubble-mediated targeted delivery of anticancer microRNA-loaded nanoparticles to deep tissues in pigs.

Author information

1
Department of Radiology, School of Medicine, Stanford University, Stanford, California, United States of America. Electronic address: todiian@stanford.edu.
2
Department of Radiology, School of Medicine, Stanford University, Stanford, California, United States of America.
3
Department of Comparative Medicine, School of Medicine, Stanford University, Stanford, California, United States of America.
4
Department of Radiology, School of Medicine, Stanford University, Stanford, California, United States of America; Department of Bioengineering, Department of Materials Science and Engineering, Stanford University, Stanford, California, United States of America.
5
Department of Radiology, School of Medicine, Stanford University, Stanford, California, United States of America. Electronic address: paulmur8@stanford.edu.

Abstract

In this study, we designed and validated a platform for ultrasound and microbubble-mediated delivery of FDA-approved pegylated poly lactic-co-glycolic acid (PLGA) nanoparticles loaded with anticancer microRNAs (miRNAs) to deep tissues in a pig model. Small RNAs have been shown to reprogram tumor cells and sensitize them to clinically used chemotherapy. To overcome their short intravascular circulation half-life and achieve controlled and sustained release into tumor cells, anticancer miRNAs need to be encapsulated into nanocarriers. Focused ultrasound combined with gas-filled microbubbles provides a noninvasive way to improve the permeability of tumor vasculature and increase the delivery efficiency of drug-loaded particles. A single handheld, curvilinear ultrasound array was used in this study for image-guided therapy with clinical-grade SonoVue contrast agent. First, we validated the platform on phantoms to optimize the microbubble cavitation dose based on acoustic parameters, including peak negative pressure, pulse length, and pulse repetition frequency. We then tested the system in vivo by delivering PLGA nanoparticles co-loaded with antisense-miRNA-21 and antisense-miRNA-10b to pig liver and kidney. Enhanced miRNA delivery was observed (1.9- to 3.7-fold increase) as a result of the ultrasound treatment compared to untreated control regions. Additionally, we used highly fluorescent semiconducting polymer nanoparticles to visually assess nanoparticle extravasation. Fluorescent microscopy suggested the presence of nanoparticles in the extravascular compartment. Hematoxylin and eosin staining of treated tissues did not reveal tissue damage. The results presented in this manuscript suggest that the proposed platform may be used to safely and noninvasively enhance the delivery of miRNA-loaded nanoparticles to target regions in deep organs in large animal models.

KEYWORDS:

Cancer treatment; Microbubbles; Nanoparticles; Targeted drug delivery; Ultrasound; microRNAs

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center